Full Press Release Details
Immunic, Inc. Announces Private Placement of
NEW YORK, January 5, 2024 - Immunic,
Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a biotechnology company developing a clinical pipeline of
orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced it has entered into a
securities purchase agreement with select accredited investors to purchase shares of common stock (or pre-funded warrants in lieu thereof)
in a three-tranche offering.
The first tranche is an upfront payment of $80
million at $1.43 per share, which is expected to close on January 8, 2024, subject to customary closing conditions. The second tranche
is a mandatory purchase of an additional $80 million of shares of common stock (or pre-funded warrants) at $1.716 per share, representing
120% of the first tranche purchase price and is conditioned on the announcement of phase 2b topline data for the Company's vidofludimus
calcium (IMU-838) progressive multiple sclerosis clinical trial, volume weighted average share price levels, and minimum trading volumes.
A third tranche, to occur no later than three years after the second tranche, provides for the issuance of $80 million of shares of common
stock (or pre-funded warrants in lieu thereof) at the same price per share as the second tranche, but permits investors to fund their
purchase obligations on a "cashless" or net settlement basis, which would reduce the proceeds to be raised in the financing.
The third tranche is conditioned on the same volume weighted average share price levels and minimum trading volumes as the second tranche.
Assuming that the second tranche is exercised, and depending on the extent to which the investors elect to fund the third tranche through
a net settlement basis, total gross proceeds from the offering to the Company would be between $160 and $240 million.
The financing is being led by BVF Partners L.P.,
and includes participation from new and existing investors, including Avidity Partners, Janus Henderson Investors, Soleus Capital, RTW
Investments and Adage Capital Partners LP.
The Company is obligated to register for resale
by the investors all of the shares of common stock issued in the offering and the shares of common stock issuable on exercise of the pre-funded
Leerink Partners is acting as the lead placement
agent and Ladenburg Thalmann is acting as a placement agent in connection with the financing. Piper Sandler, B. Riley Securities and Brookline
Capital Markets, a division of Arcadia Securities, LLC, are acting as capital markets advisors to the Company.
The Company intends to use the net proceeds from
the private placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-856
and IMU-381, and for other general corporate purposes. The proceeds from the first tranche of this private placement, combined with current
cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into the third quarter of 2025.
The securities to be sold in this offering, including
the shares of common stock issuable on exercise of the pre-funded warrants, have not been registered under the Securities Act of 1933,
as amended (the "Securities Act"), or the securities laws of any state or other jurisdiction and may not be offered
or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and
applicable state or other jurisdictions' securities laws. Immunic has agreed to file a registration statement with the U.S. Securities
and Exchange Commission registering the resale of the securities issued in the private placement. Any offering of the securities under
the resale registration statement will only be made by means of a prospectus.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology
company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.
The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for
the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials
in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis.
Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator,
with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856,
which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which
could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparations
for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically
address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding expected
future events, including the closing of each tranche of the Company's private placement financing, the timely funding to the Company
by each investor in the private placement, strategy, future operations, future financial position, future revenue, projected expenses,
sufficiency of cash, expected timing and results of clinical trials, prospects, plans and objectives of management are forward-looking
statements. Examples of such statements include, but are not limited to, statements relating to expected timing and funding to the Company
from the private placement, Immunic's development programs and the targeted diseases; the potential for Immunic's development
programs to safely and effectively target diseases; interpretation of preclinical and clinical data for Immunic's development programs
and potential effects; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and
focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the
company; and the company's expected cash runway. Immunic may not actually achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking
statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual
results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including,
without limitation, the COVID-19 pandemic, impacts of the Ukraine - Russia conflict and the conflict in the Middle East on clinical
trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future
liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational
requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial
results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development
and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions
of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors" in the company's
Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 23, 2023, and in the company's
subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking
statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these
forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims
all liability in respect to actions taken or not taken based on any or all the contents of this press release.
Head of Investor Relations and Communications
Rx Communications Group